USA flag logo/image

An Official Website of the United States Government

Search


Download to spreadsheetPrint
Displaying 51 – 75 of 126 Awards
Company: KYLIN THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2009 / 1
Abstract: DESCRIPTION (provided by applicant): pRNA Nanoparticles for Therapeutic Applications Kylin Therapeutics is developing a proprietary small interfering RNA (siRNA) delivery platform technology inspired by a naturally occurring molecule called packaging RNA ( pRNA). siRNA holds… more
Company: NOVELMED THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2009 / 1
Abstract: …. Gradual loss of vision eventually resulting in blindness is the key symptom of AMD in the adult population. Using the mouse AMD model, Bora et al demonstrated that complement factor B of t he alternative pathway plays an important role in the disease. With the use of siRNA… more
Company: NUPOTENTIAL, INC. Agency/Program/Year/Phase: HHS / STTR / 2009 / 1
Abstract: … rest ore differentiation and developmental potential of bovine donor cells for SCNT. In support of this proposal, NuPotential initially demonstrated DNA demethylation and improved developmental potential following SCNT in bovine donor cells treated with DNMT1-s pecific siRNA.… more
Company: OMEROS CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2009 / 1
Abstract: … is the same; howeve r, the fact that other inhibitors with the same specificity cannot restore the IGF-1 response indicates that a secondary target must be involved. Therefore, the objectives of this Phase I proposal are to a) identify this unique target using a siRNA… more
Company: OMEROS CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2009 / 1
Abstract: … target for these two inhibitors is the same; however, the fact that other inhibitors with the same specificity ca nnot restore the IGF-1 response indicates that a second kinase target must be involved. The specific aims of the parent grant are a) to utilize siRNA knockdowns… more
Company: RATIONAL BIOTECHNOLOGY, INC. Agency/Program/Year/Phase: HHS / SBIR / 2009 / 1
Abstract: DESCRIPTION (provided by applicant): RNA interference (RNAi), a biological process for modulating gene expression using short interfering RNA (siRNA) molecules, has emerged as one of the most promising technologies for treating a wide range of difficult-to -cure diseases,… more
Company: SIRNAOMICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2009 / 1
Abstract: … based on a growing understanding of molecular oncology. Understanding the molecular mechanisms involved in the pathogenesis of lung cancer can provide opportunities to develop innovati ve therapies for NSCLC. In this proposal, we proposed a novel multi-targeted siRNA… more
Company: TRANSDERM, INC. Agency/Program/Year/Phase: HHS / SBIR / 2009 / 2
Abstract: … small interfering RNAs (siRNAs) is now relative ly straightforward. Unfortunately, methodologies to deliver these potential therapeutics to appropriate cells (including skin cells) have not kept pace. The long-term goal of this project is to develop effective and efficient … more
Company: Ablitech, Inc. Agency/Program/Year/Phase: NSF / SBIR / 2008 / 1
Abstract: This Small Business Innovation Research (SBIR) Phase I project will demonstrate the feasibility of a platform technology for cancer therapy which overcomes the inherent shortcomings of other attempts to delivery siRNA to cancer cells. The difficulty with current … more
Company: AKTIV-DRY Agency/Program/Year/Phase: HHS / SBIR / 2008 / 1
Abstract: … and well tolerat ed in ongoing human trials focused on intranasal and aerosol delivery. Aktiv-Dry's novel, patented powder generating technology, CO2-assisted nebulization with a bubble dryer (CAN-BD(r)), will be applied to make inhalable powders of placebo and siRNA drugs … more
Company: AM BIOTECHNOLOGIES, LLC Agency/Program/Year/Phase: HHS / SBIR / 2008 / 1
Abstract: DESCRIPTION (provided by applicant): The siRNA molecule needs better protection from nuclease degradation before it can be effectively used as a therapeutic. AM Biotechnologies (AM) will address this critical issue by developing ribonucleoside thiophospho ramidite (ABz, CBz,… more
Company: ARMAGEN TECHNOLOGIES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2008 / 1
Abstract: … technology that enables the knockdown of expression of pathologic genes with short interfering RNAs (siRNAs). The limiting factor in the development of new RNAi medicines is d elivery. The goal of the field is Intravenous RNAi, which is the ability to inject a siRNA into a… more
Company: BIOO Scientific Agency/Program/Year/Phase: NSF / SBIR / 2008 / 1
Abstract: This Small Business Innovation Research (SBIR) Phase I research project aims to develop an improved method for the delivery of small inhibitory ribonucleic acids (siRNA) into cells. The proposed methodology will utilize chemically induced immuno-conjugates or direct linking of… more
Company: BIOO Scientific Agency/Program/Year/Phase: HHS / SBIR / 2008 / 1
Abstract: DESCRIPTION (provided by applicant): The overall goal of this proposal is to develop novel reagents to efficiently deliver functional siRNA into animals for gene silencing experiments. Pharmaceutical and biotechnology companies are actively testing siRNAs as therapeutic agents… more
Company: BIOTEX, INC. Agency/Program/Year/Phase: NSF / STTR / 2008 / 1
Abstract: This Small Business Technology Transfer Phase I project develops molecular biology, biochemical engineering, and purification techniques to provide small interfering RNA or siRNA molecules on at large-scale and at low cost compared to available techniques. In recent years,… more
Company: BOSTON BIOMEDICAL, INC. Agency/Program/Year/Phase: HHS / SBIR / 2008 / 1
Abstract: … and manufacturing, as well as the activation of host interferon-like responses. Of these, delivery has proved to be the major obstacle. RNAi delivery has, thus far, defied conventional approaches that f ocus mostly on various pharmaceutical technologies, such as siRNA… more
Company: EFFIGENE PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / STTR / 2008 / 1
Abstract: … base pairs. When applied to cells, siRNAs can effectively and specifically silence their target genes, called RNA interference (RNAi). RNAi has become attract ive tool for functional genomics and a potential class of molecules for human therapeutics. However, almost every … more
Company: GENUS ONCOLOGY, LLC Agency/Program/Year/Phase: HHS / SBIR / 2008 / 1
Abstract: … receptor for signaling the presence of stress to the interior of the cell. Studies of diverse human cancer cell lines have demonstrated that MUC1 attenuates anti-cancer agents-induced cell death. Moreover, knockdown of MUC1 expression in carcinoma cells by MUC1siRNA was… more
Company: Innovative Surface Technologies, Inc. Agency/Program/Year/Phase: HHS / SBIR / 2008 / 1
Abstract: DESCRIPTION (provided by applicant): This SBIR project is designed to develop a new non-viral carrier for target-specific delivery of small interfering RNA (siRNA). One of the major challenges in transforming siRNA from laboratory reagents to therapeutics is developing a… more
Company: OPTIMUM THERAPEUTICS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2008 / 1
Abstract: … particulate delivery platforms to develop intraperitoneal (IP) tumor-targeting chemo-gene therapy. Based on the res ult of preliminary study, we propose to apply the tumor priming microparticles (TPM) technology to develop IP gene therapy using small interference RNA (siRNA)… more
Company: Physical Sciences Inc. Agency/Program/Year/Phase: HHS / SBIR / 2008 / 1
Abstract: …rons has been proposed to be due to aggregation of the protein 1-synuclein. An improved targeted delivery system to neuronal cells is necessary to improve therap eutic treatment options. Physical Sciences Inc. (PSI) proposes to conjugate a targeted small interfering RNA (siRNA)… more
Company: PROGENRA, INC. Agency/Program/Year/Phase: HHS / SBIR / 2008 / 1
Abstract: …ein the functional activity of lead c ompounds from Praja1 inhibitor screens will be evaluated. The assays will assess the effects of candidate compounds on cells at both the transcriptional and bone-formation levels and will be validated by the use of Praja1 siRNA and generic… more
Company: SIRNAOMICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2008 / 1
Abstract: …going through development and trials in order to treat this malig nant disease. This proposal is to use the breakthrough RNAi technology to develop a multi-targeted therapeutics to treat breast cancer. This proposed study is to take advantage of the HKP carriers with siRNA… more
Company: TRANSDERM, INC. Agency/Program/Year/Phase: HHS / SBIR / 2008 / 1
Abstract: … are highly potent and selective, demonstrating remarkable single-nucleotide spe cificity. Clinical trials using siRNAs are currently underway for a number of indications including age- related macular degeneration and respiratory syncitial virus infection. No siRNA treatment of… more
Company: TRANSDERM, INC. Agency/Program/Year/Phase: HHS / SBIR / 2008 / 1
Abstract: … this project is to develop a mechanism to efficiently and effectively deliver siRNAs to appropriate skin cells in a way that can be readily translated to use in humans. In Phase I, we investigate a number of mouse skin reporter systems for their suitability to monitor siRNA… more
Displaying 51 – 75 of 126 Awards
Narrow Your Search
By Agency
By Year
By Phase
By Program
By State
By Company Ownership
By Company
HELP FOR NARROW YOUR SEARCH

Search Options

There are several categories such as “By Agency”, “By Year”, “By State” etc. Select a checkbox within a category to refine your search results.

Each of your selections is listed in the “Narrow Search Filters” bar. You can uncheck these selections to remove them.


Search for Either Criteria

When you select multiple values within a category, the results will include values that match either of the selections. For example, selecting “2005” and “2007” in the “By Year” category will display results that include either 2005 OR 2007 in the results.


Narrowing the Search Results

You can refine your search results across categories. To narrow down your results, select multiple values across different categories. The results will only include values that match the selections across the categories. For example, selecting “2005” in the “By Year” category and “NASA” in the “By Agency” category will only display the results that contain both “2005” AND “NASA” in the results.